Crinetics Pharmaceuticals (CRNX) Projected to Post Earnings on Thursday

Crinetics Pharmaceuticals (NASDAQ:CRNX) is projected to announce its Q4 2025 results after the market closes on Thursday, February 26th. Analysts expect the company to announce earnings of ($1.35) per share and revenue of $4.3230 million for the quarter. Individuals can find conference call details on the company’s upcoming Q4 2025 earning report page for the latest details on the call scheduled for Thursday, February 26, 2026 at 4:30 PM ET.

Crinetics Pharmaceuticals Price Performance

Crinetics Pharmaceuticals stock opened at $43.45 on Thursday. Crinetics Pharmaceuticals has a 12-month low of $24.10 and a 12-month high of $57.99. The stock has a market capitalization of $4.44 billion, a PE ratio of -9.59 and a beta of 0.19. The firm has a 50 day simple moving average of $49.52 and a 200-day simple moving average of $42.46.

Analyst Upgrades and Downgrades

A number of equities analysts have issued reports on the company. Weiss Ratings reaffirmed a “sell (d-)” rating on shares of Crinetics Pharmaceuticals in a research note on Wednesday, January 21st. Citizens Jmp lowered their target price on Crinetics Pharmaceuticals from $108.00 to $105.00 and set a “market outperform” rating on the stock in a report on Thursday, January 8th. Lifesci Capital upgraded shares of Crinetics Pharmaceuticals to a “strong-buy” rating in a research report on Friday, February 13th. Morgan Stanley boosted their target price on shares of Crinetics Pharmaceuticals from $77.00 to $80.00 and gave the stock an “overweight” rating in a report on Tuesday, January 6th. Finally, The Goldman Sachs Group upgraded shares of Crinetics Pharmaceuticals from a “neutral” rating to a “buy” rating and set a $67.00 price target on the stock in a research report on Monday, January 12th. One investment analyst has rated the stock with a Strong Buy rating, nine have issued a Buy rating and one has issued a Sell rating to the stock. According to MarketBeat.com, Crinetics Pharmaceuticals has an average rating of “Moderate Buy” and a consensus price target of $75.78.

Insider Buying and Selling

In related news, insider Isabel Kalofonos sold 2,500 shares of the firm’s stock in a transaction that occurred on Monday, January 5th. The shares were sold at an average price of $55.00, for a total value of $137,500.00. Following the completion of the transaction, the insider owned 834 shares of the company’s stock, valued at approximately $45,870. This trade represents a 74.99% decrease in their position. The transaction was disclosed in a document filed with the SEC, which is accessible through this hyperlink. Corporate insiders own 4.60% of the company’s stock.

Institutional Trading of Crinetics Pharmaceuticals

A number of hedge funds have recently modified their holdings of CRNX. Smartleaf Asset Management LLC boosted its position in shares of Crinetics Pharmaceuticals by 107.5% in the fourth quarter. Smartleaf Asset Management LLC now owns 639 shares of the company’s stock worth $30,000 after buying an additional 331 shares during the period. Headlands Technologies LLC purchased a new stake in Crinetics Pharmaceuticals in the 2nd quarter worth about $30,000. Parallel Advisors LLC boosted its position in Crinetics Pharmaceuticals by 34.6% during the 4th quarter. Parallel Advisors LLC now owns 1,225 shares of the company’s stock worth $57,000 after acquiring an additional 315 shares during the period. Arax Advisory Partners boosted its position in Crinetics Pharmaceuticals by 131.2% during the 4th quarter. Arax Advisory Partners now owns 1,498 shares of the company’s stock worth $70,000 after acquiring an additional 850 shares during the period. Finally, Raymond James Financial Inc. purchased a new position in Crinetics Pharmaceuticals during the 2nd quarter valued at about $45,000. Hedge funds and other institutional investors own 98.51% of the company’s stock.

About Crinetics Pharmaceuticals

Crinetics Pharmaceuticals, Inc is a clinical-stage biopharmaceutical company focused on the discovery, development and commercialization of novel therapeutics for rare endocrine diseases. The company’s proprietary platform leverages insights into hormone receptor signaling to design small-molecule candidates that address conditions driven by dysregulated hormone activity. Crinetics’ research efforts center on targeting somatostatin, vasopressin and other GPCR-mediated pathways with orally bioavailable molecules intended to improve patient convenience and adherence.

The company’s lead product candidate, paltusotine (formerly CRN04777), is a selective, non-peptide somatostatin receptor type 2 agonist being evaluated for the treatment of acromegaly and carcinoid syndrome diarrhea.